{"id":"NCT01268098","sponsor":"Shire","briefTitle":"Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)","officialTitle":"A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02-09","primaryCompletion":"2011-09-23","completion":"2011-11-11","firstPosted":"2010-12-29","resultsPosted":"2015-03-06","lastUpdate":"2021-06-11"},"enrollment":42,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypoparathyroidism"],"interventions":[{"type":"DRUG","name":"NPSP558","otherNames":["RELAY"]}],"arms":[{"label":"25 µg dose","type":"EXPERIMENTAL"},{"label":"50 µg dose","type":"EXPERIMENTAL"}],"summary":"Use of PTH (1-84) a recombinant hormone in 25 µg or 50 µg doses for the treatment of adults with hypoparathyroidism. The use of PTH (1-84) should result in a decrease of calcium and vitamin D supplements.","primaryOutcome":{"measure":"Percentage of Subjects Who Achieved the Primary Triple Endpoint at Week 8, Based on Investigator Prescribed Data.","timeFrame":"8 Weeks","effectByArm":[{"arm":"NPSP558 - 25 µg Dose","deltaMin":21.1,"sd":null},{"arm":"NPSP558 - 50 µg Dose","deltaMin":26.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":">0.999"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":12,"countries":["United States"]},"refs":{"pmids":["36018496","35974422","35696069","32738041","28942334"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":["Paresthesia","Muscle spasms","Nausea","Headache","Fatigue"]}}